Zenas BioPharma (ZBIO) faces a catalyst-rich 2026, with the key milestone being the planned BLA submission for obexelimab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results